35-45kDa (Reducing)
Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
· 3 months, -20 to -80℃ under sterile conditions after reconstitution.
· 1 week, 2 to 8℃ under sterile conditions after reconstitution.
· Please avoid repeated freeze-thaw cycles.
Lahoud M H. et al. (2009) The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol. 182(12): 7587-7594.
Pyz E. et al. (2008) Characterisation of murine MICL (CLEC12A) and evidence for an endogenous ligand. Eur J Immunol. 38(4): 1157-1163.
Marshall A S. et al. (2006) Human MICL (CLEC12A) is differentially glycosylated and is down-regulated following cellular activation. Eur J Immunol. 36(8): 2159-2169.
Clec12a (also called myeloid inhibitory C-type lectin-like receptor, MICL) was originally described as an ITIM-containing inhibitory CLR expressed by human granulocytes and monocytes. It was suggested that Clec12a recognizes some endogenous ligands as soluble Clec12a could bind to single-cell suspensions isolated from various murine tissues. CLEC12A is a myeloid lineage antigen that is highly expressed by AML cells and LSCs, but not expressed by normal hematopoietic stem cells (HSCs), thus minimizing off-target toxicity.
1μg (R: reducing condition, N: non-reducing condition).
Immobilized CLEC12A/MICL His Tag Protein, Cynomolgus (Cat. No. UA011058) at 2.0μg/mL (100μL/well) can bind CLEC12A Rabbit pAb (A6250) with EC50 of 0.068-0.12 μg/mL.
您现在的位置：